Samarth Kulkarni Crispr Therapeutics Ag (CRSP) insider trading activity

Samarth Kulkarni is Chief Executive Officer of CRISPR Therapeutics AG. Currently has a direct ownership of 195,085 shares of CRSP, which is worth approximately $6.64 Million. The most recent transaction as insider was on Dec 05, 2022, when has been sold 19,401 shares (Common Shares) at a price of $52.26 per share, resulting in proceeds of $1,013,896. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 195K

0.11% 3M change

6.26% 12M change

Total Value Held $6.64 Million

Samarth Kulkarni Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 05 2022	SELL Payment of exercise price or tax liability	$1,013,896 $52.26 p/Share	19,401 Reduced 5.87%	310,878 Common Shares
Dec 03 2022	BUY Exercise of conversion of derivative security	-	40,000 Added 10.8%	330,279 Common Shares
Nov 28 2022	SELL Open market or private sale	$1,365,250 $54.61 p/Share	25,000 Reduced 7.93%	290,279 Common Shares
Nov 28 2022	BUY Exercise of conversion of derivative security	$478,000 $19.12 p/Share	25,000 Added 7.35%	315,279 Common Shares
Oct 26 2022	SELL Open market or private sale	$1,359,000 $54.36 p/Share	25,000 Reduced 7.93%	290,279 Common Shares
Oct 26 2022	BUY Exercise of conversion of derivative security	$441,750 $17.67 p/Share	25,000 Added 7.35%	315,279 Common Shares
Sep 28 2022	SELL Open market or private sale	$1,619,500 $64.78 p/Share	25,000 Reduced 7.93%	290,279 Common Shares
Sep 28 2022	BUY Exercise of conversion of derivative security	$405,250 $16.21 p/Share	25,000 Added 7.35%	315,279 Common Shares
Aug 29 2022	SELL Open market or private sale	$1,673,000 $66.92 p/Share	25,000 Reduced 7.93%	290,279 Common Shares
Aug 29 2022	BUY Exercise of conversion of derivative security	$405,250 $16.21 p/Share	25,000 Added 7.35%	315,279 Common Shares
Jul 27 2022	SELL Open market or private sale	$1,915,750 $76.63 p/Share	25,000 Reduced 7.93%	290,279 Common Shares
Jul 27 2022	BUY Exercise of conversion of derivative security	$359,750 $14.39 p/Share	25,000 Added 7.35%	315,279 Common Shares
Jun 29 2022	SELL Open market or private sale	$1,546,750 $61.87 p/Share	25,000 Reduced 7.93%	290,279 Common Shares
Jun 29 2022	BUY Exercise of conversion of derivative security	$314,250 $12.57 p/Share	25,000 Added 7.35%	315,279 Common Shares
Mar 14 2022	SELL Payment of exercise price or tax liability	$253,665 $61.08 p/Share	4,153 Reduced 1.41%	290,279 Common Shares
Mar 11 2022	SELL Payment of exercise price or tax liability	$343,267 $62.56 p/Share	5,487 Reduced 1.89%	285,432 Common Shares
Mar 11 2022	BUY Exercise of conversion of derivative security	-	9,000 Added 2.97%	294,432 Common Shares
Mar 10 2022	BUY Exercise of conversion of derivative security	-	11,834 Added 3.91%	290,919 Common Shares
Dec 20 2021	BUY Exercise of conversion of derivative security	$32,127 $1.81 p/Share	17,750 Added 5.98%	279,085 Common Shares
Dec 06 2021	SELL Payment of exercise price or tax liability	$2,615,871 $69.17 p/Share	37,818 Reduced 12.64%	261,335 Common Shares
Dec 03 2021	BUY Exercise of conversion of derivative security	-	80,000 Added 21.1%	299,153 Common Shares
Dec 01 2021	SELL Payment of exercise price or tax liability	$58,503 $75.1 p/Share	779 Reduced 0.35%	219,153 Common Shares
Oct 15 2021	BUY Exercise of conversion of derivative security	$59,730 $1.81 p/Share	33,000 Added 13.05%	219,932 Common Shares
Sep 01 2021	SELL Payment of exercise price or tax liability	$98,241 $124.83 p/Share	787 Reduced 0.42%	186,932 Common Shares
Aug 05 2021	SELL Open market or private sale	$3,668,805 $128.73 p/Share	28,500 Reduced 13.18%	187,719 Common Stock

Also insider at

BDTX

Black Diamond Therapeutics, Inc. Healthcare

RPTX

Repare Therapeutics Inc. Healthcare

CNTA

Centessa Pharmaceuticals plc Healthcare

Director